• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Glenmark receives ANDA approval for Ranolazine Extended-Release Tablets

biospectrumasiaJuly 09, 2019

Tag: Glenmark , ANDA , Ranolazine Extended-Release Tablets

Glenmark Pharmaceuticals Inc. has been granted final approval by the United States Food & Drug Administration for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg, a generic version of Ranexa® Extended-Release Tablets, 500 mg and 1,000 mg, of Gilead Sciences, Inc.

According to IQVIATM sales data for the 12 month period ending May 2019, the Ranexa® Extended-Release Tablets, 500 mg and 1,000 mg market2 achieved annual sales of approximately $929.0 million.

Glenmark’s current portfolio consists of 158 products authorized for distribution in the U.S. marketplace and 57 ANDA’s pending approval with the USFDA.

Previous:AG Mednet, Median Technologies to conduct clinical programs in China

Next:Daewoong Pharmaceutical introduced the excellence of NABOTA® (Prabotulinumtoxin A)

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Glenmark receives ANDA approval for Ranolazine Extended-Release Tablets | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Standard HVAC System Toiletry/ ICU/ Pharmaceutical/ Hospital/ Medical/ Lab/ Electronics/ Food Cleanr

Standard HVAC System Toiletry/ ICU/ Pharmaceutical/ Hospital/ Medical/ Lab/ Electronics/ Food Cleanr
EP standard Diosmin Hesperidin 90:10

EP standard Diosmin Hesperidin 90:10
Pressure vessel and non - standard series

Pressure vessel and non - standard series
High standard and safety Human Immunoglobulin without preservatiivesand antibiotics

High standard and safety Human Immunoglobulin without preservatiivesand antibiotics
LGJ-50FD Standard Type Experimental Freeze Dryer

LGJ-50FD Standard Type Experimental Freeze Dryer
The LUMiFrac CAT TECHNOLOGY: THE NEW STANDARD IN ADHESION TESTING

The LUMiFrac CAT TECHNOLOGY: THE NEW STANDARD IN ADHESION TESTING
pharmaceutical Oxytocin Acetate(GMP standard product) Peptide

pharmaceutical Oxytocin Acetate(GMP standard product) Peptide
High standard Human Thrombin, Lyophilized for external use without preservatives

High standard Human Thrombin, Lyophilized for external use without preservatives

Flame Retardant Grade Expandable Polystyrene

Flame Retardant Grade Expandable Polystyrene
High-standard Influenza Vaccine (Split virion), inactivated

High-standard Influenza Vaccine (Split virion), inactivated

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service